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Summary objective Artemether-lumefantrine (AL), presently the most favoured combination therapy against
uncomplicated Plasmodium falciparum malaria in Africa, has recently shown to select for the pfmdr1
86N allele. The objective of this study was to search for the selection of other mutations potentially
involved in artemether-lumefantrine tolerance and/or resistance, i.e. pfmdr1 gene amplification, pfmdr1
Y184F, S1034C, N1042D, D1246Y, pfcrt S163R and PfATP6 S769N.
methods The above mentioned SNPs were analysed by PCR–restriction fragment length poly-
morphism and pfmdr1 gene amplification by real-time PCR based protocols in parasites from 200
children treated with AL for uncomplicated P. falciparum malaria in Zanzibar.
results A statistically significant selection of pfmdr1 184F mostly in combination with 86N was seen
in reinfections after treatment. No pfmdr1 gene amplification was found.
conclusion The results suggest that different pfmdr1 alleles are involved in the development of
tolerance/resistance to lumefantrine.
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Introduction
Plasmodium falciparum malaria kills more than two
million people annually, mostly in Africa. Artemisinin
based combination therapy (ACT) is being promoted as the
main policy in response to increasing resistance to common
monotherapies. A fixed dose combination of the artemis-
inin derivative artemether and the arylaminoalcohol drug
lumefantrine (Coartem; Novartis, AG) is presently the
mostly favoured ACT and has, therefore, recently been
introduced as first or second line treatment in several
African countries.
Single nucleotide polymorphisms (SNPs) in the
P. falciparum multidrug resistance gene 1 (pfmdr1) have
been associated with altered in vitro and in vivo parasite
response to arylaminoalcohols (Duraisingh & Cowman
2005), including lumefantrine (Duraisingh et al. 2000).
We have previously reported that in vivo exposure to
artemether-lumefantrine (AL) selects for pfmdr1 86N in
new inoculations (reinfections) post-treatment (Sisowath
et al. 2005). Due to this finding, it has been suggested that
the selection of 86N may represent a marker of tolerance
to lumefantrine (Hastings & Ward 2005), where tolerant
parasites, being in the intermediate stage between sensitive
and resistant, are killed by the high drug levels during
treatment but can withstand residual lumefantrine con-
centrations and proliferate in the blood earlier than
sensitive.
The genetic basis of in vivo resistance to AL remains
unclear and, therefore, we have explored several additional
factors of potential importance in development of AL
tolerance/resistance such as: (1) Is amplification of the
pfmdr1 gene selected in recurrent infections after AL
treatment in Zanzibar as it has been observed to influence
mefloquine (Price et al. 2004) and lumefantrine (Price et al.
2006) susceptibility in Southeast Asia? (2) Is the selection
of pfmdr1 86N allele just a marker of the selection of the
gene amplification as this SNP is associated with amplifi-
cation (Price et al. 2004; Uhlemann et al. 2005)? (3) Are
other pfmdr1 SNPs associated with arylaminoalcohol
resistance (Woodrow & Krishna 2006) selected among the
recurrent parasites? (4) Is the P. falciparum chloroquine
resistance transporter (pfcrt) S163R SNP, previously
associated with in vitro resistance to halofantrine
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(Johnson et al. 2004) selected? (5) Is the product of the
newly isolated sarco/endoplasmic reticulum Ca2+-ATPase
orthologue of P. falciparum (PfATP6) associated with the
few recrudescences observed in our study, potentially due
to a lower response to the artemether component of the
drug combination? This has been suggested as a pharma-
cological target of artemisinin derivatives (Krishna et al.
2006), and a field study in South America has shown an
association between the PfATP6 S769N SNP and a
significant decrease in sensitivity to artemether (Jambou
et al. 2005).
The aim of this study was to address these questions in
samples collected during a clinical trial of AL treatment in
children with uncomplicated malaria in Zanzibar
(Martensson et al. 2005; Sisowath et al. 2005), before AL
was introduced as second line treatment on the islands.
Methods
Patients
In a previously published clinical trial conducted between
October 2002 and February 2003 in Zanzibar, 200
children with microscopically confirmed uncomplicated
P. falciparum malaria were treated under supervision with
AL in standard doses according to body weight twice
daily for 3 days (Martensson et al. 2005; Sisowath et al.
2005). Drug intake was not necessarily accompanied by a
fatty meal, although this is considered to enhance drug
absorption. All children were checked routinely for para-
site presence on days 0, 1, 2, 3, 7, 14, 21, 28, 35, and 42,
and at any time fever was recorded between the scheduled
days. Finger prick blood samples were collected on filter
paper (3MM; Whatman). Informed consent was obtained
from parents or legal guardians of the enrolled children.
The study was approved by the Zanzibar Health Research
Council, the World Health Organization (WHO –
SCRISM) in Geneva and the Karolinska Institutet Ethical
Committees.
Molecular analysis
Blood samples from the day of enrolment (day 0) and day
of recurrent infection were analysed at the Malaria
Research Unit, Karolinska Institutet, Stockholm, and at
the Division of Cellular and Molecular Medicine,
St George’s University of London.
Stepwise genotyping of P. falciparum merozoite surface
protein 2 (pfmsp2) and 1 (pfmsp1) genes was performed to
distinguish recrudescences from reinfections as described
by Mugittu et al. (2006). Recurrent infections classified
as recrudescences following pfmsp2 genotyping
(Sisowath et al. 2005) were subjected to additional pfmsp1
genotyping, using established protocols with minor
adjustments (Snounou et al. 1999). Recrudescence was
defined as the presence of at least one matching allelic band
from day 0 and day of recurrent infection for both the
pfmsp2 and pfmsp1 marker. Reinfections were defined as
the absence of matching bands either after pfmsp2 or
pfmsp1 genotyping. A negative PCR result on either
pfmsp2 or pfmsp1 analysis was considered as uncertain.
The pfmdr1 N86Y (Sisowath et al. 2005), Y184F,
S1034C, N1042D, D1246Y and the pfcrt S163R SNPs
were analysed by conventional PCR-restriction fragment
length polymorphism (RFLP) based protocols for all
baseline and recurrent infections. The endonuclease
restriction enzyme ApoI (New England Biolabs) was
used for the recognition of pfmdr1 86N, Tsp509I
(New England Biolabs), or the Fermentas isoschizomer
TasI was used for the recognition of 184F; DdeI
(New England Biolabs) for 1034S; AseI (New England
Biolabs) or the isoschizomer VspI (Fermentas) for 1042N;
EcoRV (New England Biolabs) for 1246Y; and HinfI
(New England Biolabs) for the recognition of pfcrt 163R.
The PfATP6 S769N SNP was analysed through a semi-nest
PCR-RFLP for recrudescent infections defined by pfmsp2
only, according to the definition of recrudescence used in
our previous report (Sisowath et al. 2005). Oligonucleotide
primers were: 1st fw 5¢-AAT TCA TAA TAA GAT TCA
AAA TAT GGG AAA-3¢; 1st rev 5¢-GAT CAA TAA TAC
CTA ATC CAC CTA AAT AAA-3¢; semi nest rev 5¢-ATC
TGT ATT CTT AAT ATT TAA ATC TTT AGT A-3¢. The
769S allele was identified by the restriction enzyme RsaI
(New England Biolabs). Restriction fragments were ana-
lysed by electrophoresis in 2% agarose gels. PCR–RFLP
results were confirmed by automated sequencing
(Megabace 1000, Amersham Biosciences). Taq polymerase
was from Promega. All PCR reactions were performed in
GeneAmp PCR System 2700 thermocyclers (Applied
Biosystems).
Assessment of pfmdr1 copy number was performed as
previously described by TaqMan probe based real-time
PCR protocols at St George’s University of London
(ABI PRISM 7700 Sequence Detection System; Applied
Biosystems) and at the Karolinska Institutet in Stockholm
(ABI PRISM 7000 Sequence Detection System) (Price
et al. 2004). The multiplex PCR reactions contained
1·TaqMan buffer (Applied Biosystems), 300 nM of each
primer, 100 nM of each probe and 5–10 ll of DNA in a
total reaction volume of 25 ll. All samples were run in
triplicate. The P. falciparum clone 3D7 was used as a one
copy calibrator and Dd2 was used as a multi-copy control.
The results were analysed by the comparative DDCt (cycle
threshold) method. Results of triple replicate samples were
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excluded if: (1) more than one replicate exhibited a
Ct > 35; (2) the triple replicate samples had Ct SD > 0.5
and the Ct difference between the two remaining replicates
was > 0.7 after the removal of any outlier. The parasites
were considered to have an amplified pfmdr1 gene if copy
number was > 1.5.
Statistical analysis
When determining the prevalence of individual SNP alleles,
mixed infections contribute equally to each of the studied
allele, as described in our previous report (Sisowath et al.
2005). As for the haplotype analysis of pfmdr1 position 86
in combination with 184 or 1246, if any of the two
analysed SNP positions in the haplotype analysis were both
wild type and mutant allele, the infection was considered to
consist of two different haplotypes. If both the SNPs had
wild type and mutant alleles, the sample was excluded
from that haplotype analysis. 95% confidence intervals
were calculated with CIA (Confidence Interval Analysis)
program. Yates’ corrected chi-square testing was per-
formed with the Microstat software. Statistical signifi-
cance was defined as a P-value £ 0.05.
Results
Out of 200 children included in the study, three children
were lost to follow-up. Forty-five episodes with recurrent
parasitaemia were recorded, the earliest on day 21. One
recurrent episode was excluded because of a previous
retreatment with another drug. As reported previously, 189
baseline and 39 recurrent infections were PCR positive for
pfmsp2, pfcrt position 76 and pfmdr1 86 (Sisowath et al.
2005). By initial pfmsp2 analysis, 11 of the recurrent
episodes were defined as recrudescences and 28 as rein-
fections. After additional pfmsp1 analysis, only 2 out of 11
remained recrudescences, while 7 were reclassified as
reinfections and 2 were considered uncertain due to
negative PCR outcome with the pfmsp1 marker.
None of the 186 successfully analysed baseline isolates
had an amplified pfmdr1 gene, neither had any recurrent
infections. Of all the herein SNPs analysed, allelic vari-
ation was only observed in pfmdr1 positions 184 and
1246. As for the remaining pfmdr1 S1034C, N1042D,
pfcrt S163R and PfATP6 S769N SNPs, all parasite
isolates had the wild type allele.
The pfmdr1 184F prevalence showed a 2.1 fold increase
in reinfections from 16.6% to 35.5% (P ¼ 0.027)
(Table 1). When combining this result with our previously
published data on N86Y, an association between the 86N/
184F haplotype and reinfections was seen (Table 2). The
statistically significant selection of this haplotype
(P ¼ 0.001) was followed by a similar decrease in the
prevalence of 86Y/184Y (P ¼ 0.009), while the remaining
two haplotypes (86Y/184F and 86N/184Y) were not
affected.
The pfmdr1 1246D allele prevalence was 66.8% prior to
treatment and 83.9% among reinfecting parasites
(P ¼ 0.086) (Table 1). The selection of 1246D in combi-
nation with 86N was specifically significant in reinfecting
parasites (P ¼ 0.001). This selection was not at the cost
of any specific allele (Table 2). Both pfmdr1 86N and
184F SNPs were selected mainly in the early reinfections
(Figure 1).
Two recrudescences were found after stepwise genotyp-
ing. Both had pfmdr1 184Y alleles, while in positions
86/1246 the respective recrudescence had N/D and Y/Y
alleles. The small number of recrudescences did not allow
any meaningful analysis of selection potential.
Discussion
Artemether-lumefantrine presently represents the most
important drug for the treatment of uncomplicated malaria
in the post-chloroquine and sulfadoxine-pyrimethamine
era in Africa. Understanding the molecular basis of
progression from susceptibility via tolerance to resistance
of P. falciparum against this combination is fundamental
Table 1 Pfmdr1 SNPs N86Y, Y184F and D1246Y before treatment and in reinfections.
pfmdr1 SNPs
Day 0 Reinfections
n A + B/C + B 95% CI n A + B/C + B 95% CI P-value
86N 29 + 20/189 + 20 23.4 (17.7–29.2) 15 + 3/35 + 3 47.4 (31.0–64.2) 0.004
184F 22 + 8/173 + 8 16.6 (11.2–22.0) 10 + 1/30 + 1 35.5 (19.2–54.6) 0.027
1246D 108 + 47/185 + 47 66.8 (60.8–72.9) 25 + 1/30 + 1 83.9 (66.3–94.5) 0.086
For the SNP analysis a mixed infection was considered to contribute equally for both SNP alleles. To calculate the frequency of the studied
allele, the number of mixed infections harbouring both wild type and mutant alleles (B) was added to the number of infections carrying
only the allele of interest (A). Mixed infections (B) was also added to the total numbers of successfully analysed infections (C).
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for the establishment of measures to protect it from
premature dismissal. Understanding the molecular basis for
tolerance and resistance and having molecular markers for
its surveillance will provide more solid ground for appro-
priate drug polices. Markers of tolerance, indicating
emerging resistance, will enable decision makers to change
to more effective drugs before resistance has reached
deleterious levels.
We have previously identified the pfmdr1 86N allele as a
potential marker of tolerance to lumefantrine (Sisowath
et al. 2005). In this follow-up work, we have re-examined
samples from the same trial to assess the possible contri-
bution of other tentative molecular factors in the
P. falciparum response to exposure of both lumefantrine
and artemether.
In particular, pfmdr1 gene amplification has been
established as a contributor to altered in vivo parasite
response to arylaminoalcohols (Cowman et al. 1994;
Duraisingh et al. 2000; Price et al. 2004; Price et al. 2006).
Our results support that pfmdr1 amplification is presently
rare in this region of Africa, because these are in
agreement with other recent observations from Uganda
(Dokomajilar et al. 2006) and Kenya (Holmgren et al.
2006), whereas in Southeast Asia, the prevalence can be up
to 50% (Price et al. 2006). The reasons for this current
rarity of pfmdr1 amplification in East Africa are unclear,
but may be related to a parasite fitness cost associated with
counter selection by the vast use of chloroquine on the
continent. Parasites selected for high levels of chloroquine
resistance have been shown to deamplify pfmdr1 (Barnes
et al. 1992). It is also possible that the lack of selection of
pfmdr1 amplification by AL may be due to low selection
pressure or a result of the combination per se, including the
documented synergistic effect of the two compounds
Pfmdr1  86 
Pfmdr1  184 
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Figure 1 Distribution of pfmdr1 N86Y,
Y184F and D1246Y SNPs of the 28 pfmsp2
adjusted Plasmodium falciparum reinfec-
tions during the 42-day follow-up period.
Infections with pfmdr1 86N alleles are
being selected particularly in the early
reinfections, while in the later reinfections
on day 42 the 86Y and 86N frequencies
have returned towards the baseline
frequency. A similar finding was seen for
pfmdr1 Y184F.
Table 2 Pfmdr1 86/184 and 86/1246 haplotypes before treatment and in reinfections
pfmdr1 haplotypes
Day 0 Reinfections
n 95% CI n 95% CI P-value
86N + 184Y 27/190 14.2 (9.3–19.2) 6/33 18.2 (7.0–35.5) 0.743
86Y + 184Y 134/190 70.5 (64.0–77.0) 15/33 45.5 (28.1–63.7) 0.009
86N + 184F 16/190 8.4 (4.9–13.3) 10/33 30.3 (15.6–48.7) 0.001
86Y + 184F 13/190 6.8 (3.7–11.4) 2/33 6.1 (0.7–20.2) 0.833
86N + 1246Y 3/230 1.3 (0.3–3.8) 0/33 0 (0–10.6) 0.829
86Y + 1246Y 67/230 29.1 (23.3–35.0) 5/33 15.2 (5.1–31.9) 0.140
86N + 1246D 39/230 17.0 (12.1–21.8) 14/33 42.4 (25.5–60.8) 0.001
86Y + 1246D 121/230 52.6 (46.2–59.1) 14/33 42.4 (25.5–60.8) 0.364
For the haplotype analysis only infections being successfully analysed for both the amino acid positions of the haplotype (86 and 184 or 86
and 1246) were included. A mixed infection in one of the SNP was considered as two different haplotypes. If both the SNPs were mixed
infections the sample was excluded from that haplotype analysis.
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(Hassan Alin et al. 1999). In Gabon, low frequencies of
pfmdr1 amplification were found after treatment with
mefloquine as monotherapy (Uhlemann et al. 2005),
suggesting that selection of gene amplification may occur
if lumefantrine would be used alone in Africa.
The two recrudescent infections found in this study
could not be explained by enhanced pfmdr1 copy
number. Recent data from in vivo trials in Southeast
Asia (Price et al. 2006) showed that pfmdr1 amplifica-
tion was only associated with treatment failure following
a four-dose regimen of AL and low lumefantrine plasma
levels (Price et al. 2006). Our study used the standard six
dose regimen, but we do not know if the two treatment
failures were caused by insufficient drug bioavailability
since lumefantrine plasma concentrations are not avail-
able.
A wide range of susceptibility levels to arylaminoalcoh-
ols has been seen without the presence of pfmdr1 ampli-
fication (Basco et al. 1995; Ritchie et al. 1996; Chaiyaroj
et al. 1999; Johnson et al. 2004; Price et al. 2004),
suggesting that other factors such as SNPs could be
involved in the development of tolerance and resistance.
In our study, there was a selection of pfmdr1 genes
carrying the 1246D allele among reinfecting parasites,
although not statistically significant (P ¼ 0.086) possibly
due to the established high frequency already at baseline.
A significant selection of the combined 86N/1246D hapl-
otype was, however, observed (P ¼ 0.001). The 1246D
SNP may thus represent a secondary marker of the
response to lumefantrine. Pfmdr1 184F harbouring para-
sites were also found to be selected, specifically in early
reinfections (Figure 1). Again, we observed a co-selection
with 86N; the reason for the association is presently
unclear, but may involve a compensating mechanism or a
combined contribution to decreased drug susceptibility,
e.g. enhanced substrate (drug) binding due to combined
changes in the amino acid side chains. The selection of the
1246D and 184F alleles after AL treatment is in agreement
with recent findings from Uganda where ACT has not yet
been implemented (Dokomajilar et al. 2006). Whether the
pfmdr1 1246D, 184F and 86N SNPs all take part in a
development of resistance to lumefantrine or rather
represent compensating mechanisms to maintain or
increase parasite fitness remains unclear.
The pfcrt S163R SNP, a recently proposed marker of
in vitro resistance to arylaminoalcohols, was not found,
confirming the previous reports of its rarity in vivo
(Johnson et al. 2004). It is notable that this SNP was
selected in vitro from a background of pfmdr1 86Y (strain
K1) (Ritchie et al. 1996), which is not usually associated
with decreased arylaminoalcohol sensitivity in vivo (Price
et al. 2004; Sisowath et al. 2005).
Finally, for the first time, the PfATP6 769N allele,
recently associated to decrease artemisinin susceptibility
(Jambou et al. 2005), was investigated in an ACT efficacy
trial. However, this SNP was detected neither at baseline
nor among the previously pfmsp2 defined 11 recrudes-
cences. This mutation may represent a geographically
specific variant as it has so far only been detected in South
America (Jambou et al. 2005).
In conclusion, our results confirm the involvement of
pfmdr1 in lumefantrine tolerance in vivo. The path to
resistance to AL may involve a marked selection of
86N/184F and 86N/1246D haplotypes. Pfmdr1 amplifi-
cation was not present in our study, but may potentially
represent a further development towards resistance with
increased selection pressure of lumefantrine in Africa.
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Roˆle de pfmdr1 dans la tole´rance de Plasmodium falciparum a` l’artemether-lumefantrine en Afrique
objectif L’artemether-lumefantrine (AL), la the´rapie de combinaison actuellement pre´fe´re´e pour la malaria non complique´e a` Plasmodium falciparum
en Afrique a e´te´ re´cemment rapporte´e comme se´lectionnant pour l’alle`le 86N de pfmdr1. L’objectif de cette e´tude est de rechercher la se´lection d’autres
mutations potentiellement implique´es dans la tole´rance et/ou la re´sistance a` AL, c’est-a`-dire l’amplification du ge`ne pfmdr1, pfmdr1 Y184F, S1034C,
N1042D, D1246Y, pfcrt S163R et PfATP6 S769N.
me´thodes Les SNP ci-dessus mentionne´s ont e´te´ analyse´s par PCR-RFLP et l’amplification du ge`ne pfmdr1 par des protocoles de PCR en temps re´el
chez des parasites provenant de 200 enfants traite´s avec AL pour la malaria non complique´e a` P. falciparum a` Zanzibar.
re´sultats Une se´lection statistiquement significative de pfmdr1 184F, en combinaison souvent avec 86N a e´te´ observe´e dans les re´infections apre`s
traitement. Aucune amplification du ge`ne pfmdr1 n’a e´te´ observe´e.
conclusion Les re´sultats sugge`rent que les diffe´rents alle`les pfmdr1 sont implique´s dans le de´veloppement de la tole´rance/ re´sistance au lumefantrine.
mots cle´s malaria, Plasmodium falciparum, lumefantrine, re´sistance, pfmdr1
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El papel de pfmdr1 en la tolerancia de Plasmodium falciparum a artemeter-lumefantrina en A´frica
objetivo Artemeter-lumefantrina (AL), actualmente la terapia de combinacio´n ma´s favorecida contra la malaria no complicada por Plasmodium
falciparum en A´frica, ha demostrado recientemente seleccionar el alelo 86N de pfmdr1. El objetivo de este estudio era buscar la seleccio´n de otras
mutaciones potencialmente involucradas en la tolerancia y/o resistencia a AL, por ejemplo amplificacio´n del gen pfmdr1, pfmdr1 Y184F, S1034C,
N1042D, D1246Y, pfcrt S163R y PfATP6 S769N.
me´todos Se analizaron las variantes gene´ticas que afectan un u´nico nucleo´tido (singular nuclear polymorphisms - SNP) mediante PCR-RFLP y la
amplificacio´n del gen pfmdr1 se realizo´ mediante protocolos basados en PCR a tiempo real en para´sitos provenientes de 200 nin˜os tratados con AL para
malaria no complicada por P. falciparum en Zanzibar.
resultados Se observo´ una seleccio´n estadı´sticamente significativa de pfmdr1 184F principalmente en combinacio´n con 86N en reinfecciones despue´s
del tratamiento. No se encontro´ ninguna amplificacio´n del gen pfmdr1.
conclusio´n Los resultados sugieren que diferentes alelos de pfmdr1 esta´n involucrados en el desarrollo de tolerancia / resistencia a la lumefantrina.
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